HYFT MindWalk Holdings Corp.

$HYFT I believe we’re entering NEWS SEASON for MindWalk. There are a LOT of potential catalysts sitting on the table right now: 1. Neutralization data The science needs to keep validating what MindWalk has built. Strong results could materially advance the internal pipeline. 2. Cayman Islands financing Management said the legal/tax work was ~90–95% complete. Then MindWalk adds Kim Remizowski — 35+ years in Cayman banking, private equity, funds and investment structures — to the board. Interesting timing. 3. Bigger Big Pharma contracts MindWalk is already talking about contracted, recurring ReefIQ deployments. Now give us names, dollars and evidence that ReefIQ can be duplicated across Big Pharma. 4. AMD + Vultr AMD isn’t just a logo on a slide. MindWalk has been showcased at AMD events. AMD published a dedicated MindWalk case study. AMD + Vultr infrastructure is powering its OpenFold3 deployment. And management specifically told us there is “MORE TO COME” regarding this relationship. 5. ReefIQ commercial numbers How many deployments? ARR per customer? Contract length? Expansion potential? Once investors can put real numbers behind recurring ReefIQ revenue, they can start putting a real valuation on the platform. 6. Internal pipeline financing/partnerships Completing the Cayman structure is one thing. Putting outside capital into individual MindWalk drug programs is another. If MindWalk can advance assets with outside capital while retaining meaningful economics, that’s a potentially important part of the model. 7. $30M Sanabil facility Confirmation that the facility is fully operational would give MindWalk another source of capital as these programs and ReefIQ scale. 8. WILD CARD — another board addition They just added serious Cayman financial expertise. What happens if the next addition brings Big Pharma or major AI/infrastructure experience? Any ONE of these moves the story forward. Start stacking several together and $HYFT begins looking like a very different company than the one the market is valuing today. The pieces are on the board. Now let’s see the news.

$HYFT WAKE UP. READ WHAT MANAGEMENT ACTUALLY SAID. This isn't “we launched ReefIQ and hope someone buys it.”MULTIPLE LARGE PHARMA companies are already negotiating enterprise deployments. One potential customer has worked with MindWalk FOR YEARS, already has a SaaS subscription, and has been negotiating across MULTIPLE JURISDICTIONS for quite some time. CEO Jennifer Bath:“We have a very good line of sight on where and how this is going and when we anticipate it closing.”And it gets better. ReefIQ opportunities are SUBSTANTIALLY LARGER than historical LensAI agreements.🔥 80% of the pipeline BY VALUE is shifting toward partnership structures. New partnerships can include UPFRONT PAYMENTS + MILESTONES + ROYALTIES. Majority of early ReefIQ interest is coming from LARGE PHARMA. $30M unsecured credit facility. NO equity issuance.🔥 And that DOESN'T replace separate asset-level financing — management says those Cayman structures are already 90–95% through the legal/tax setup, with interested investors. The Street is staring at $3.8M quarterly revenue. I'm staring at WHAT THIS BUSINESS COULD LOOK LIKE AFTER THE FIRST MAJOR REEFIQ DEAL CLOSES. NAME THE PARTNER. SHOW US THE CONTRACT!

$HYFT Honestly, it’s hard to find another biotech company besides $HYFT with a low-CapEx, high-ROI business model. Most biotech companies make money through outsourcing or successful drug development, but those models are far less stable and carry much higher risk. In theory, $HYFT has one of the strongest business models in biotech. Management aside, of course lol.

$HYFT One of the most significant days in MindWalk’s history: • 💰 $30M unsecured credit facility • 🚫 No warrants / conversion / collateral • 🚫 No equity raise • 📈 Revenue +21% • 📈 Gross profit +47% • 📈 Gross margin 59% • Multiple LARGE PHARMA companies negotiating ReefIQ enterprise deployments • ReefIQ deals potentially SUBSTANTIALLY LARGER than historical LensAI agreements • 80% of the funnel BY VALUE now partnership structured • Upfronts + milestones + royalties + shared asset economics • Existing relationships with 19 of the TOP 20 global pharma companies AND WHAT'S STILL AHEAD? 👀 • 🔥 AMD + Vultr + OpenFold 3 results THIS WEEK • 🔥 First major ReefIQ enterprise deal • 🔥 Additional pharma partnerships • 🔥 Asset-level financing — Cayman structure 90–95% complete • 🔥 Internal therapeutic pipeline catalysts Bath says they have “a very good line of sight” on where the ReefIQ negotiations are going. Nothing is guaranteed. Execution is everything. But after TODAY? I'M NOT LOOKING FOR THE EXIT. I'M WATCHING WHAT COMES NEXT.

$HYFT this will be 10$ in 12 months, this stock is one of the most assymetric opportunities on market right now.

$HYFT MindWalk Lands Binding Commitment for US$30 Million Unsecured Credit Facility to Fund Biologics Programs and Commercial Expansion

$HYFT Honesty anything under a buck fiddy (1.50 for all you Eagles fans) is a good entry 🍺🍔🏈👍

$HYFT the opportunity cost on this stock is about…1000%. Not even kidding. I am out and will start spreading the news of this slow dilution scam…fuck Bath.

$HYFT well that 7% pretty solid tbh with the rate hike. Just get some GOD DAMN DEALS SIGNED

$HYFT It was extremely bullish! what more do you want? A company with a $60M market cap, working with the largest biotech companies in the world, and has one of the most sophisticated AI drug discovery platforms. They’re not newcomers to this. they’ve been working with these companies for decades.

$HYFT released a production deployment of OpenFold3 on AMD-powered Vultr cloud, cutting antibody-antigen inference time ~5×.

$HYFT the title of this news article says it all: Mindwalk Holdings Earnings Call Highlights ReefIQ Push. If your tech is good, clients are chasing you. No need to push.

$HYFT Q1 '27 Earnings Results & Recap • Reported GAAP EPS of -$0.09 down -50.00% YoY • Reported revenue of $2.73M up 19.74% YoY

$HYFT Mindwalk (nasdaq: hyft): enterprise ai has found its ontology layer. biology needs one grounded in biological function

$HYFT Not enough confirmation lately. Even though the price is consolidating at new supports, the price action hasn’t shown any significant growth.

$HYFT locked in a $30 million unsecured revolving credit facility with Sanabil to fund its biologics programs and commercial expansion.